Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 12 entries
Sorted by: Best Match Show Resources per page
fMRI orientation decoding in V1 does not require global maps or globally coherent orientation stimuli.

Frontiers in psychology

Alink A, Krugliak A, Walther A, Kriegeskorte N.
PMID: 23964251
Front Psychol. 2013 Aug 12;4:493. doi: 10.3389/fpsyg.2013.00493. eCollection 2013.

The orientation of a large grating can be decoded from V1 functional magnetic resonance imaging (fMRI) data, even at low resolution (3-mm isotropic voxels). This finding has suggested that columnar-level neuronal information might be accessible to fMRI at 3T....

Cite
Alink A, Krugliak A, Walther A, et al. fMRI orientation decoding in V1 does not require global maps or globally coherent orientation stimuli. Front Psychol. 2013;4:493doi: 10.3389/fpsyg.2013.00493.
Alink, A., Krugliak, A., Walther, A., & Kriegeskorte, N. (2013). fMRI orientation decoding in V1 does not require global maps or globally coherent orientation stimuli. Frontiers in psychology, 4493. https://doi.org/10.3389/fpsyg.2013.00493
Alink, Arjen, et al. "fMRI orientation decoding in V1 does not require global maps or globally coherent orientation stimuli." Frontiers in psychology vol. 4 (2013): 493. doi: https://doi.org/10.3389/fpsyg.2013.00493
Alink A, Krugliak A, Walther A, Kriegeskorte N. fMRI orientation decoding in V1 does not require global maps or globally coherent orientation stimuli. Front Psychol. 2013 Aug 12;4:493. doi: 10.3389/fpsyg.2013.00493. eCollection 2013. PMID: 23964251; PMCID: PMC3740242.
Copy Download .nbib Format: NLM
Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα.

Gastroenterology

Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Rabinowitz KM, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Golan MA, Shachar E, Ben-Horin S, Perets TT, Ben Zvi H, Eliakim R, Barkan R, Goren S, Navon M, Krugliak N, Werbner M, Alter J, Dessau M, Gal-Tanamy M, Freund NT, Cohen D, Dotan I.
PMID: 34717923
Gastroenterology. 2021 Oct 28; doi: 10.1053/j.gastro.2021.10.029. Epub 2021 Oct 28.

BACKGROUND & AIM: Patients with inflammatory bowel diseases (IBD), specifically those treated with anti-tumor necrosis factor (TNF)α biologics, are at high risk for vaccine-preventable infections. Their ability to mount adequate vaccine responses is unclear. The aim of the study...

Cite
Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, et al. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα. Gastroenterology. 2021;doi: 10.1053/j.gastro.2021.10.029.
Edelman-Klapper, H., Zittan, E., Bar-Gil Shitrit, A., Rabinowitz, K. M., Goren, I., Avni-Biron, I., Ollech, J. E., Lichtenstein, L., Banai-Eran, H., Yanai, H., Snir, Y., Pauker, M. H., Friedenberg, A., Levy-Barda, A., Segal, A., Broitman, Y., Maoz, E., Ovadia, B., Golan, M. A., Shachar, E., Ben-Horin, S., Perets, T. T., Ben Zvi, H., Eliakim, R., Barkan, R., Goren, S., Navon, M., Krugliak, N., Werbner, M., Alter, J., Dessau, M., Gal-Tanamy, M., Freund, N. T., Cohen, D., Dotan, I. (2021). Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα. Gastroenterology, . https://doi.org/10.1053/j.gastro.2021.10.029
Edelman-Klapper, Hadar, et al. "Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα." Gastroenterology vol. (2021). doi: https://doi.org/10.1053/j.gastro.2021.10.029
Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Rabinowitz KM, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Golan MA, Shachar E, Ben-Horin S, Perets TT, Ben Zvi H, Eliakim R, Barkan R, Goren S, Navon M, Krugliak N, Werbner M, Alter J, Dessau M, Gal-Tanamy M, Freund NT, Cohen D, Dotan I. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα. Gastroenterology. 2021 Oct 28; doi: 10.1053/j.gastro.2021.10.029. Epub 2021 Oct 28. PMID: 34717923; PMCID: PMC8552587.
Copy Download .nbib Format: NLM
Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα.

Gastroenterology

Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Rabinowitz KM, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Golan MA, Shachar E, Ben-Horin S, Perets TT, Ben Zvi H, Eliakim R, Barkan R, Goren S, Navon M, Krugliak N, Werbner M, Alter J, Dessau M, Gal-Tanamy M, Freund NT, Cohen D, Dotan I.
PMID: 34717923
Gastroenterology. 2021 Oct 28; doi: 10.1053/j.gastro.2021.10.029. Epub 2021 Oct 28.

BACKGROUND & AIM: Patients with inflammatory bowel diseases (IBD), specifically those treated with anti-tumor necrosis factor (TNF)α biologics, are at high risk for vaccine-preventable infections. Their ability to mount adequate vaccine responses is unclear. The aim of the study...

Cite
Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, et al. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα. Gastroenterology. 2021;doi: 10.1053/j.gastro.2021.10.029.
Edelman-Klapper, H., Zittan, E., Bar-Gil Shitrit, A., Rabinowitz, K. M., Goren, I., Avni-Biron, I., Ollech, J. E., Lichtenstein, L., Banai-Eran, H., Yanai, H., Snir, Y., Pauker, M. H., Friedenberg, A., Levy-Barda, A., Segal, A., Broitman, Y., Maoz, E., Ovadia, B., Golan, M. A., Shachar, E., Ben-Horin, S., Perets, T. T., Ben Zvi, H., Eliakim, R., Barkan, R., Goren, S., Navon, M., Krugliak, N., Werbner, M., Alter, J., Dessau, M., Gal-Tanamy, M., Freund, N. T., Cohen, D., Dotan, I. (2021). Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα. Gastroenterology, . https://doi.org/10.1053/j.gastro.2021.10.029
Edelman-Klapper, Hadar, et al. "Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα." Gastroenterology vol. (2021). doi: https://doi.org/10.1053/j.gastro.2021.10.029
Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Rabinowitz KM, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Golan MA, Shachar E, Ben-Horin S, Perets TT, Ben Zvi H, Eliakim R, Barkan R, Goren S, Navon M, Krugliak N, Werbner M, Alter J, Dessau M, Gal-Tanamy M, Freund NT, Cohen D, Dotan I. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα. Gastroenterology. 2021 Oct 28; doi: 10.1053/j.gastro.2021.10.029. Epub 2021 Oct 28. PMID: 34717923; PMCID: PMC8552587.
Copy Download .nbib Format: NLM
Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα.

Gastroenterology

Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Rabinowitz KM, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Golan MA, Shachar E, Ben-Horin S, Perets TT, Ben Zvi H, Eliakim R, Barkan R, Goren S, Navon M, Krugliak N, Werbner M, Alter J, Dessau M, Gal-Tanamy M, Freund NT, Cohen D, Dotan I.
PMID: 34717923
Gastroenterology. 2021 Oct 28; doi: 10.1053/j.gastro.2021.10.029. Epub 2021 Oct 28.

BACKGROUND & AIM: Patients with inflammatory bowel diseases (IBD), specifically those treated with anti-tumor necrosis factor (TNF)α biologics, are at high risk for vaccine-preventable infections. Their ability to mount adequate vaccine responses is unclear. The aim of the study...

Cite
Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, et al. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα. Gastroenterology. 2021;doi: 10.1053/j.gastro.2021.10.029.
Edelman-Klapper, H., Zittan, E., Bar-Gil Shitrit, A., Rabinowitz, K. M., Goren, I., Avni-Biron, I., Ollech, J. E., Lichtenstein, L., Banai-Eran, H., Yanai, H., Snir, Y., Pauker, M. H., Friedenberg, A., Levy-Barda, A., Segal, A., Broitman, Y., Maoz, E., Ovadia, B., Golan, M. A., Shachar, E., Ben-Horin, S., Perets, T. T., Ben Zvi, H., Eliakim, R., Barkan, R., Goren, S., Navon, M., Krugliak, N., Werbner, M., Alter, J., Dessau, M., Gal-Tanamy, M., Freund, N. T., Cohen, D., Dotan, I. (2021). Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα. Gastroenterology, . https://doi.org/10.1053/j.gastro.2021.10.029
Edelman-Klapper, Hadar, et al. "Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα." Gastroenterology vol. (2021). doi: https://doi.org/10.1053/j.gastro.2021.10.029
Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Rabinowitz KM, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Golan MA, Shachar E, Ben-Horin S, Perets TT, Ben Zvi H, Eliakim R, Barkan R, Goren S, Navon M, Krugliak N, Werbner M, Alter J, Dessau M, Gal-Tanamy M, Freund NT, Cohen D, Dotan I. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα. Gastroenterology. 2021 Oct 28; doi: 10.1053/j.gastro.2021.10.029. Epub 2021 Oct 28. PMID: 34717923; PMCID: PMC8552587.
Copy Download .nbib Format: NLM
Identification of SARS-CoV-2 E Channel Blockers from a Repurposed Drug Library.

Pharmaceuticals (Basel, Switzerland)

Tomar PPS, Krugliak M, Arkin IT.
PMID: 34201587
Pharmaceuticals (Basel). 2021 Jun 23;14(7). doi: 10.3390/ph14070604.

SARS-CoV-2, the etiological agent of the COVID-19 pandemic, is a member of the Coronaviridae family. It is an enveloped virus with ion channels in its membrane, the most characterized of which is the E protein. Therefore, in an attempt...

Cite
Tomar PPS, Krugliak M, Arkin IT. Identification of SARS-CoV-2 E Channel Blockers from a Repurposed Drug Library. Pharmaceuticals (Basel). 2021;14(7)doi: 10.3390/ph14070604.
Tomar, P. P. S., Krugliak, M., & Arkin, I. T. (2021). Identification of SARS-CoV-2 E Channel Blockers from a Repurposed Drug Library. Pharmaceuticals (Basel, Switzerland), 14(7), . https://doi.org/10.3390/ph14070604
Tomar, Prabhat Pratap Singh, et al. "Identification of SARS-CoV-2 E Channel Blockers from a Repurposed Drug Library." Pharmaceuticals (Basel, Switzerland) vol. 14,7 (2021). doi: https://doi.org/10.3390/ph14070604
Tomar PPS, Krugliak M, Arkin IT. Identification of SARS-CoV-2 E Channel Blockers from a Repurposed Drug Library. Pharmaceuticals (Basel). 2021 Jun 23;14(7). doi: 10.3390/ph14070604. PMID: 34201587; PMCID: PMC8308726.
Copy Download .nbib Format: NLM
Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα.

Gastroenterology

Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Rabinowitz KM, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Golan MA, Shachar E, Ben-Horin S, Perets TT, Ben Zvi H, Eliakim R, Barkan R, Goren S, Navon M, Krugliak N, Werbner M, Alter J, Dessau M, Gal-Tanamy M, Freund NT, Cohen D, Dotan I.
PMID: 34717923
Gastroenterology. 2021 Oct 28; doi: 10.1053/j.gastro.2021.10.029. Epub 2021 Oct 28.

BACKGROUND & AIM: Patients with inflammatory bowel diseases (IBD), specifically those treated with anti-tumor necrosis factor (TNF)α biologics, are at high risk for vaccine-preventable infections. Their ability to mount adequate vaccine responses is unclear. The aim of the study...

Cite
Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, et al. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα. Gastroenterology. 2021;doi: 10.1053/j.gastro.2021.10.029.
Edelman-Klapper, H., Zittan, E., Bar-Gil Shitrit, A., Rabinowitz, K. M., Goren, I., Avni-Biron, I., Ollech, J. E., Lichtenstein, L., Banai-Eran, H., Yanai, H., Snir, Y., Pauker, M. H., Friedenberg, A., Levy-Barda, A., Segal, A., Broitman, Y., Maoz, E., Ovadia, B., Golan, M. A., Shachar, E., Ben-Horin, S., Perets, T. T., Ben Zvi, H., Eliakim, R., Barkan, R., Goren, S., Navon, M., Krugliak, N., Werbner, M., Alter, J., Dessau, M., Gal-Tanamy, M., Freund, N. T., Cohen, D., Dotan, I. (2021). Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα. Gastroenterology, . https://doi.org/10.1053/j.gastro.2021.10.029
Edelman-Klapper, Hadar, et al. "Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα." Gastroenterology vol. (2021). doi: https://doi.org/10.1053/j.gastro.2021.10.029
Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Rabinowitz KM, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Golan MA, Shachar E, Ben-Horin S, Perets TT, Ben Zvi H, Eliakim R, Barkan R, Goren S, Navon M, Krugliak N, Werbner M, Alter J, Dessau M, Gal-Tanamy M, Freund NT, Cohen D, Dotan I. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα. Gastroenterology. 2021 Oct 28; doi: 10.1053/j.gastro.2021.10.029. Epub 2021 Oct 28. PMID: 34717923; PMCID: PMC8552587.
Copy Download .nbib Format: NLM
Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα.

Gastroenterology

Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Rabinowitz KM, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Golan MA, Shachar E, Ben-Horin S, Perets TT, Ben Zvi H, Eliakim R, Barkan R, Goren S, Navon M, Krugliak N, Werbner M, Alter J, Dessau M, Gal-Tanamy M, Freund NT, Cohen D, Dotan I.
PMID: 34717923
Gastroenterology. 2021 Oct 28; doi: 10.1053/j.gastro.2021.10.029. Epub 2021 Oct 28.

BACKGROUND & AIM: Patients with inflammatory bowel diseases (IBD), specifically those treated with anti-tumor necrosis factor (TNF)α biologics, are at high risk for vaccine-preventable infections. Their ability to mount adequate vaccine responses is unclear. The aim of the study...

Cite
Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, et al. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα. Gastroenterology. 2021;doi: 10.1053/j.gastro.2021.10.029.
Edelman-Klapper, H., Zittan, E., Bar-Gil Shitrit, A., Rabinowitz, K. M., Goren, I., Avni-Biron, I., Ollech, J. E., Lichtenstein, L., Banai-Eran, H., Yanai, H., Snir, Y., Pauker, M. H., Friedenberg, A., Levy-Barda, A., Segal, A., Broitman, Y., Maoz, E., Ovadia, B., Golan, M. A., Shachar, E., Ben-Horin, S., Perets, T. T., Ben Zvi, H., Eliakim, R., Barkan, R., Goren, S., Navon, M., Krugliak, N., Werbner, M., Alter, J., Dessau, M., Gal-Tanamy, M., Freund, N. T., Cohen, D., Dotan, I. (2021). Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα. Gastroenterology, . https://doi.org/10.1053/j.gastro.2021.10.029
Edelman-Klapper, Hadar, et al. "Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα." Gastroenterology vol. (2021). doi: https://doi.org/10.1053/j.gastro.2021.10.029
Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Rabinowitz KM, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Golan MA, Shachar E, Ben-Horin S, Perets TT, Ben Zvi H, Eliakim R, Barkan R, Goren S, Navon M, Krugliak N, Werbner M, Alter J, Dessau M, Gal-Tanamy M, Freund NT, Cohen D, Dotan I. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα. Gastroenterology. 2021 Oct 28; doi: 10.1053/j.gastro.2021.10.029. Epub 2021 Oct 28. PMID: 34717923; PMCID: PMC8552587.
Copy Download .nbib Format: NLM
Chloroquine - some open questions on its antimalarial mode of action and resistance.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Ginsburg H, Krugliak M.
PMID: 11504489
Drug Resist Updat. 1999 Jun;2(3):180-187. doi: 10.1054/drup.1999.0085.

During the digestion of its host cell hemoglobin, large amounts of toxic ferriprotoporphyrin IX (FPIX) are generated in the intraerythrocytic malaria parasite. FPIX is detoxified either by being polymerized into hemozoin inside the food vacuole, or through its degradation...

Cite
Ginsburg H, Krugliak M. Chloroquine - some open questions on its antimalarial mode of action and resistance. Drug Resist Updat. 1999;2(3):180-187doi: 10.1054/drup.1999.0085.
Ginsburg, H., & Krugliak, M. (1999). Chloroquine - some open questions on its antimalarial mode of action and resistance. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2(3), 180-187. https://doi.org/10.1054/drup.1999.0085
Ginsburg, Hagai, and Krugliak, Miriam. "Chloroquine - some open questions on its antimalarial mode of action and resistance." Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy vol. 2,3 (1999): 180-187. doi: https://doi.org/10.1054/drup.1999.0085
Ginsburg H, Krugliak M. Chloroquine - some open questions on its antimalarial mode of action and resistance. Drug Resist Updat. 1999 Jun;2(3):180-187. doi: 10.1054/drup.1999.0085. PMID: 11504489.
Copy Download .nbib Format: NLM
Associations Between Crohn's Disease Severity And Specific Socio-Demographic, Quality-Of-Life And Coping Factors.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Friger M, Sarid O, Slonim-Nevo V, Vardi H, Greenberg D, Ben YG, Gaspar N, Dizengof V, Moshkelo A, Munteau D, Rozental A, Abu FN, Schwartz D, Krugliak P, Eidelman L, Fich A, Odes S.
PMID: 27200749
Value Health. 2014 Nov;17(7):A363. doi: 10.1016/j.jval.2014.08.802. Epub 2014 Oct 26.

No abstract available.

Cite
Friger M, Sarid O, Slonim-Nevo V, et al. Associations Between Crohn's Disease Severity And Specific Socio-Demographic, Quality-Of-Life And Coping Factors. Value Health. 2014;17(7):A363doi: 10.1016/j.jval.2014.08.802.
Friger, M., Sarid, O., Slonim-Nevo, V., Vardi, H., Greenberg, D., Ben, Y. G., Gaspar, N., Dizengof, V., Moshkelo, A., Munteau, D., Rozental, A., Abu, F. N., Schwartz, D., Krugliak, P., Eidelman, L., Fich, A., & Odes, S. (2014). Associations Between Crohn's Disease Severity And Specific Socio-Demographic, Quality-Of-Life And Coping Factors. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A363. https://doi.org/10.1016/j.jval.2014.08.802
Friger, M, et al. "Associations Between Crohn's Disease Severity And Specific Socio-Demographic, Quality-Of-Life And Coping Factors." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A363. doi: https://doi.org/10.1016/j.jval.2014.08.802
Friger M, Sarid O, Slonim-Nevo V, Vardi H, Greenberg D, Ben YG, Gaspar N, Dizengof V, Moshkelo A, Munteau D, Rozental A, Abu FN, Schwartz D, Krugliak P, Eidelman L, Fich A, Odes S. Associations Between Crohn's Disease Severity And Specific Socio-Demographic, Quality-Of-Life And Coping Factors. Value Health. 2014 Nov;17(7):A363. doi: 10.1016/j.jval.2014.08.802. Epub 2014 Oct 26. PMID: 27200749.
Copy Download .nbib Format: NLM
Auditory motion capturing ambiguous visual motion.

Frontiers in psychology

Alink A, Euler F, Galeano E, Krugliak A, Singer W, Kohler A.
PMID: 22232613
Front Psychol. 2012 Jan 02;2:391. doi: 10.3389/fpsyg.2011.00391. eCollection 2012.

In this study, it is demonstrated that moving sounds have an effect on the direction in which one sees visual stimuli move. During the main experiment sounds were presented consecutively at four speaker locations inducing left or rightward auditory...

Cite
Alink A, Euler F, Galeano E, et al. Auditory motion capturing ambiguous visual motion. Front Psychol. 2012;2:391doi: 10.3389/fpsyg.2011.00391.
Alink, A., Euler, F., Galeano, E., Krugliak, A., Singer, W., & Kohler, A. (2012). Auditory motion capturing ambiguous visual motion. Frontiers in psychology, 2391. https://doi.org/10.3389/fpsyg.2011.00391
Alink, Arjen, et al. "Auditory motion capturing ambiguous visual motion." Frontiers in psychology vol. 2 (2012): 391. doi: https://doi.org/10.3389/fpsyg.2011.00391
Alink A, Euler F, Galeano E, Krugliak A, Singer W, Kohler A. Auditory motion capturing ambiguous visual motion. Front Psychol. 2012 Jan 02;2:391. doi: 10.3389/fpsyg.2011.00391. eCollection 2012. PMID: 22232613; PMCID: PMC3249388.
Copy Download .nbib Format: NLM
Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα.

Gastroenterology

Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Rabinowitz KM, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Golan MA, Shachar E, Ben-Horin S, Perets TT, Ben Zvi H, Eliakim R, Barkan R, Goren S, Navon M, Krugliak N, Werbner M, Alter J, Dessau M, Gal-Tanamy M, Freund NT, Cohen D, Dotan I.
PMID: 34717923
Gastroenterology. 2021 Oct 28; doi: 10.1053/j.gastro.2021.10.029. Epub 2021 Oct 28.

BACKGROUND & AIM: Patients with inflammatory bowel diseases (IBD), specifically those treated with anti-tumor necrosis factor (TNF)α biologics, are at high risk for vaccine-preventable infections. Their ability to mount adequate vaccine responses is unclear. The aim of the study...

Cite
Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, et al. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα. Gastroenterology. 2021;doi: 10.1053/j.gastro.2021.10.029.
Edelman-Klapper, H., Zittan, E., Bar-Gil Shitrit, A., Rabinowitz, K. M., Goren, I., Avni-Biron, I., Ollech, J. E., Lichtenstein, L., Banai-Eran, H., Yanai, H., Snir, Y., Pauker, M. H., Friedenberg, A., Levy-Barda, A., Segal, A., Broitman, Y., Maoz, E., Ovadia, B., Golan, M. A., Shachar, E., Ben-Horin, S., Perets, T. T., Ben Zvi, H., Eliakim, R., Barkan, R., Goren, S., Navon, M., Krugliak, N., Werbner, M., Alter, J., Dessau, M., Gal-Tanamy, M., Freund, N. T., Cohen, D., Dotan, I. (2021). Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα. Gastroenterology, . https://doi.org/10.1053/j.gastro.2021.10.029
Edelman-Klapper, Hadar, et al. "Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα." Gastroenterology vol. (2021). doi: https://doi.org/10.1053/j.gastro.2021.10.029
Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Rabinowitz KM, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Golan MA, Shachar E, Ben-Horin S, Perets TT, Ben Zvi H, Eliakim R, Barkan R, Goren S, Navon M, Krugliak N, Werbner M, Alter J, Dessau M, Gal-Tanamy M, Freund NT, Cohen D, Dotan I. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα. Gastroenterology. 2021 Oct 28; doi: 10.1053/j.gastro.2021.10.029. Epub 2021 Oct 28. PMID: 34717923; PMCID: PMC8552587.
Copy Download .nbib Format: NLM
Local opposite orientation preferences in V1: fMRI sensitivity to fine-grained pattern information.

Scientific reports

Alink A, Walther A, Krugliak A, Kriegeskorte N.
PMID: 28769042
Sci Rep. 2017 Aug 02;7(1):7128. doi: 10.1038/s41598-017-07036-8.

The orientation of a visual grating can be decoded from human primary visual cortex (V1) using functional magnetic resonance imaging (fMRI) at conventional resolutions (2-3 mm voxel width, 3T scanner). It is unclear to what extent this information originates...

Cite
Alink A, Walther A, Krugliak A, et al. Local opposite orientation preferences in V1: fMRI sensitivity to fine-grained pattern information. Sci Rep. 2017;7(1):7128doi: 10.1038/s41598-017-07036-8.
Alink, A., Walther, A., Krugliak, A., & Kriegeskorte, N. (2017). Local opposite orientation preferences in V1: fMRI sensitivity to fine-grained pattern information. Scientific reports, 7(1), 7128. https://doi.org/10.1038/s41598-017-07036-8
Alink, Arjen, et al. "Local opposite orientation preferences in V1: fMRI sensitivity to fine-grained pattern information." Scientific reports vol. 7,1 (2017): 7128. doi: https://doi.org/10.1038/s41598-017-07036-8
Alink A, Walther A, Krugliak A, Kriegeskorte N. Local opposite orientation preferences in V1: fMRI sensitivity to fine-grained pattern information. Sci Rep. 2017 Aug 02;7(1):7128. doi: 10.1038/s41598-017-07036-8. PMID: 28769042; PMCID: PMC5540976.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 12 entries